Bottom line
Is MSVIX a good fund? The bottom line
MSVIX is the Institutional share class of MetLife Small Company Equity Fund, a managed small-cap mutual fund from SEI.
Its expense ratio is 0.99% — about $99 a year on every $10,000 invested, more expensive than 51% of small-cap funds we track.
It returned +9.0% over one year, +11.0% a year over five years (as of Dec 31, 2025, per its prospectus).
With $7.9 million in net assets and 78 holdings, its largest position is N/a (3.7%) and the top 10 make up 19.7% of the portfolio.
What stands out
- 5-year return beat 90% of category peers
What to watch
- Small fund ($7.9 million) — small funds are likelier to close
Updated Nov 19, 2026
What MSVIX invests in
The MetLife Small Company Equity Fund (the Small Company Equity Fund or the Fund) seeks to provide long-term capital appreciation with less volatility than the U.S. small company market.
Under normal circumstances, the Fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of small companies. This investment policy may be changed by the Fund upon 60 days prior written notice to shareholders. For purposes of the Funds 80% policy, equity securities include common stocks and exchange-traded funds (ETFs) with economic characteristics similar to equity securities. The Fund considers small companies to be those with market capitalizations within the range of the market capitalizations of companies in the Russell 2500 Index at the time of purchase, and ETFs that aim to replicate or produce returns that generally correspond to small company indexes. The market capitalization range of the Russell 2500 Index was approximately $24 million to $32.5 billion as of September 30, 2025, and may change over time. At any given time…
From the fund's prospectus (filed Jan 28, 2026).
MSVIX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| MSVIX | +9.0% | +11.0% | — |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What MSVIX costs
On a $10,000 investment, MSVIX's 0.99% expense ratio costs about $99 a year. The prospectus estimates $2,487 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
MSVIX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | N/a | 3.67% |
| 2 | Halozyme Therapeutics, Inc. | 1.99% |
| 3 | Kontoor Brands, Inc. | 1.99% |
| 4 | SPDR Series Trust - SPDR S&P Biotech ETF | 1.88% |
| 5 | Advanced Energy Industries, Inc. | 1.85% |
| 6 | Praxis Precision Medicines Inc | 1.75% |
| 7 | iShares Russell 2000 ETF | 1.72% |
| 8 | Zions Bancorporation, National Association | 1.66% |
| 9 | Gates Industrial Corporation Plc | 1.64% |
| 10 | Standardaero, Inc. | 1.60% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 19.7% of the fund. See all top 25 holdings and asset mix →